New York is currently home to 4599 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma
Recruiting
The primary objective of our study is to determine the efficacy of combined topical cysteamine cream with a 1927 diode non-ablative laser (Clear + Brilliant Permea®; Solta Medical, Inc.), compared to topical cysteamine (Cyspera) alone in the treatment of melasma. The main questions it aims to answer are If melasma treatment with topical cysteamine cream is more effective when used with the Clear & Brilliant® Permea laser The safety & efficacy of melasma treatment in various skin types using th... Read More
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
12/15/2022
Locations: UnionDerm, New York, New York
Conditions: Melasma
Heart Failure Monitoring With Eko Electronic Stethoscopes (CardioMEMS)
Recruiting
This study will enroll heart failure (HF) patients who are under active management with an implanted pulmonary artery pressure sensor (CardioMEMS). Subjects will be provided an electronic stethoscope (the Eko DUO) to take at-home heart sound, lung sound, and ECG recordings in conjunction with regimented CardioMEMS measurements. These two datasets will be used to confirm whether an AI/ML model to track HF status can be developed.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2022
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Heart Failure
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Recruiting
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2022
Locations: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Primary Radiotherapy for the Treatment of Keloids: A Pilot Study
Recruiting
This will be a single-institution pilot study to evaluate the safety and efficacy of radiation therapy (RT) for the treatment of unresected keloids. The primary endpoint will be toxicity within 10 weeks of follow-up. Secondary endpoints will include cessation of growth or shrinkage of keloids, symptomatic response, and impact on quality of life.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/11/2022
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Safety and Efficacy of Radiation Therapy for the Treatment of Keloids
TruGraf® Long-term Clinical Outcomes Study
Recruiting
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Kidney Transplant Rejection
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
Recruiting
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiogra... Read More
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
11/07/2022
Locations: Hospital for Special Surgery, New York, New York
Conditions: Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes
Recruiting
This study will use continuous glucose monitoring and actigraphy to examine whether a personalized, daily sleep extension intervention improves glucose regulation for community dwelling, sleep-restricted adults with pre-diabetes. The randomized controlled trial will include 150 adults with pre-diabetes. Sleep extension and habitual sleep groups will complete daily sleep diaries and participate in a weekly 15-minute telephone call or videoconference meeting with a member of the study team (8 sess... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
11/04/2022
Locations: NYU Langone, New York, New York
Conditions: PreDiabetes
Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)
Recruiting
A Randomized Controlled Multicenter Clinical Trial, Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) and Standard of Care versus Standard of Care alone in the healing Chronic Diabetic Foot Ulcers. Multi-center, open label, randomized controlled trial. Study is estimated to require 12 months from first subject enrolled to last subject visit.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Mount Sinai St. Luke's Hospital, New York, New York
Conditions: Chronic Diabetic Foot Ulcers
HIPEC After Initial CRS in Patients Who Have Received NACT
Recruiting
The majority of women diagnosed with ovarian, fallopian tube and primary peritoneal cancer present with advanced stage III and IV disease. Despite aggressive surgery and systemic chemotherapy, the majority of patients will relapse. Five year survival remains only 20-35% for patients diagnosed with bulky stage IIIC and IV cancers. Patients who are not candidates for an initial cytoreductive surgery at the time of diagnosis form a particularly poor prognosis group. These patients are treated with... Read More
Gender:
Female
Ages:
Between 18 years and 85 years
Trial Updated:
11/01/2022
Locations: Long Island Jewish Medical Center, New Hyde Park, New York
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Informatics Framework for Pulmonary Rehabilitation
Recruiting
Previous studies clearly established clinical benefits of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease however uptake and completion rate of pulmonary rehabilitation programs by these patients is limited by multiple barriers. The goal of this project to systematically evaluate impact of Comprehensive Health Informatics Engagement Framework for Pulmonary Rehabilitation (CHIEF-PR) in a randomized controlled trial. The main hypothesis is that CHIEF-PR will result... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/28/2022
Locations: Mount Sinai Hospital, New York, New York
Conditions: COPD
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: NYU Langone Orthopedic Hospital, New York, New York
Conditions: Symptomatic Cervical Disc Disease
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
Recruiting
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of previously untreated corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Riboflavin 0.23% PESCHKE-L Solution) administered in conjunction with the UV-A li... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: SightMD, Babylon, New York
Conditions: Keratitis, Corneal Ulcer